Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel

Abstract

Purpose: Results of several clinical studies suggest that the combination of doxorubicin (DOX) and paclitaxel (PTX) is highly active against solid tumors. Both drugs are known to cause adverse cardiac effects, cardiomyopathy in the case of DOX and acute changes in cardiac rhythm in the case of PTX. It has been suggested that the addition of dexrazoxane (DZR… (More)
DOI: 10.1007/s002800050958

Topics

  • Presentations referencing similar topics